Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00404339 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Head and Neck Cancer
A Phase 1 study, sponsored by Robert Ferris.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00404339: Completed Phase 1 study, sponsored by Robert Ferris.
NCT00404339 is a Phase 1 study that has completed, run by Robert Ferris. The registered enrollment target is 17 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00404339, a Phase 1 study, has completed, sponsored by Robert Ferris.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from a person's dendritic cells mixed with peptides may help the body build an effective immune response to kill tumor cells. PURPOSE: This randomized phase I trial is studying the side effects of vaccine therapy in treating patients with head and neck cancer.
Interventions
- PROCEDURE adjuvant therapy
- BIOLOGICAL tetanus toxoid helper peptide
- BIOLOGICAL mutant p53 peptide pulsed dendritic cell vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2005-09 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
What the finished NCT00404339 record still lists
NCT00404339 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 3 interventions - of which adjuvant therapy is the first listed.
NCT00404339 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00404339 about?
NCT00404339 is a clinical study titled "Vaccine Therapy in Treating Patients With Head and Neck Cancer". RATIONALE: Vaccines made from a person's dendritic cells mixed with peptides may help the body build an effective immune response to kill tumor cells. PURPOSE: This randomized phase I trial is studying the side effects of vaccine therapy in treating patients with head and neck cancer.
What is the current status of trial NCT00404339?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2005-09. Estimated completion is 2014-03.
What interventions are being tested in trial NCT00404339?
The interventions under investigation include: adjuvant therapy (PROCEDURE), tetanus toxoid helper peptide (BIOLOGICAL), mutant p53 peptide pulsed dendritic cell vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00404339?
This trial is sponsored by Robert Ferris, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00404339's enrollment target sits among peer trials
17 1785th of 2000 higher than 215 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia